Knight Therapeutics, Inc. (GUD.TO)
9.66
0.00 (0.00%)
CAD |
TSX |
Aug 24, 16:00
Knight Therapeutics Gross Profit Margin (Quarterly) : 38.94% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 38.94% |
| March 31, 2026 | 36.67% |
| December 31, 2025 | 38.23% |
| September 30, 2025 | 33.21% |
| June 30, 2025 | 31.76% |
| March 31, 2025 | 28.83% |
| December 31, 2024 | 30.68% |
| September 30, 2024 | 36.68% |
| June 30, 2024 | 37.31% |
| March 31, 2024 | 35.60% |
| December 31, 2023 | 31.13% |
| September 30, 2023 | 35.22% |
| June 30, 2023 | 29.16% |
| March 31, 2023 | 35.83% |
| December 31, 2022 | 24.16% |
| September 30, 2022 | 25.12% |
| June 30, 2022 | 35.93% |
| March 31, 2022 | 33.21% |
| December 31, 2021 | 19.14% |
| September 30, 2021 | 36.22% |
| June 30, 2021 | 32.28% |
| March 31, 2021 | 33.16% |
| December 31, 2020 | 21.87% |
| September 30, 2020 | 30.57% |
| June 30, 2020 | 30.86% |
| Date | Value |
|---|---|
| March 31, 2020 | 30.15% |
| December 31, 2019 | 43.62% |
| September 30, 2019 | 68.09% |
| June 30, 2019 | 73.91% |
| March 31, 2019 | 59.13% |
| December 31, 2018 | 73.61% |
| September 30, 2018 | 65.28% |
| June 30, 2018 | 64.16% |
| March 31, 2018 | 59.07% |
| December 31, 2017 | 63.36% |
| September 30, 2017 | 52.90% |
| June 30, 2017 | 68.06% |
| March 31, 2017 | 64.91% |
| December 31, 2016 | 65.91% |
| September 30, 2016 | 79.07% |
| June 30, 2016 | 41.23% |
| March 31, 2016 | 72.38% |
| December 31, 2015 | 73.76% |
| September 30, 2015 | 58.77% |
| June 30, 2015 | 9.71% |
| March 31, 2015 | 53.56% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| HLS Therapeutics, Inc. | 42.90% |
| Bausch Health Cos., Inc. | 65.04% |
| Cipher Pharmaceuticals, Inc. | 65.58% |
| BioSyent, Inc. | 65.02% |
| Revive Therapeutics Ltd. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 1.91% |
| Return on Assets | 1.41% |
| Return on Invested Capital | 1.74% |
| Profit Margin (Quarterly) | -2.33% |
| Operating Margin (Quarterly) | 6.21% |
| Return on Net Operating Assets | 1.98% |